Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

PACT Pharma

Company Type: Therapeutics

Main focus: Engineering of T cells

Company stage: Pre-clinical

Diseases: Immune-oncology

Genome-editing tool: CRISPR/Cas

Funding stage: Series C

Location: Hayward, California, USA

Website: https://pactpharma.com

Pipeline: pactpharma.com/programs/

Partners:

PACT is a clinical-stage privately held biopharmaceutical company pioneering individualised and off-the-shelf, non-viral precision genome engineered, tumour-specific T cell receptor (TCR) T cell therapies for the treatment of patients with solid cancers.

Your Latest CMN News

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

CMN Weekly (12 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

Scientists use CRISPR to develop new detection...

Scientists in China describe a sensitive and selective CRISPR-Cas12-based assay for the detection of a protein that is implicated in obesity and...

Company: PACT Pharma

Search CRISPR Medicine